Scilex Relaunch Elyxyb (celecoxib oral solution) in the US for Migraine Treatment

Shots:

The company reported the commercial availability of Elyxyb (celecoxib oral solution), the ready-to-use oral solution formulation of celecoxib for the acute treatment of migraine with/out aura in the US.
Elyxyb is expected to be available in the US in Q2’23 through its wholly owned subsidiary, Scilex & has been approved in the US on May 2020 for the treatment of acute migraine with or without aura in adults, based on the 2 P-III trials.
Elyxyb is now available in pharmacies as an oral solution in glass bottles with a celecoxib concentration of 25mg per mL (120mg/4.8 mL) & the maximum dosage in a 24hr. period is 120mg. The company also strengthen its leadership position in non-opioid pain management

Ref: Globenewswire | Image: Scilex

Related News:- Scilex Acquires Rights for Elyxyb to Treat Migraine in the US and Canada